Elan submits MS data for trial drug Antegren

Irish pharmaceutical firm Elan and partner Biogen announced today that they have submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for the approval of Antegren for the treatment of multiple sclerosis (MS).

The submission includes one-year data from two ongoing Phase III trials, part of a two-year trial period that both companies have committed to.

Data from these trials is not being disclosed at this time.

Lars Ekman, executive vice president and president, R&D at Elan said today: "This submission represents a significant milestone for Elan and Biogen Idec and demonstrates our continued commitment to providing a new treatment option for the more than one million patients experiencing the debilitating effects of MS."

Multiple sclerosis (MS) is a chronic disease of the central nervous system that affects more than 1.5 million people worldwide.